A phase I trial of allogeneic Tumour-activated natural killer lymphocytes after low dose TBI and fludarabine for the treatment of selected patients with acute myeloid leukaemia.

Trial Profile

A phase I trial of allogeneic Tumour-activated natural killer lymphocytes after low dose TBI and fludarabine for the treatment of selected patients with acute myeloid leukaemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2015

At a glance

  • Drugs CNDO 109 (Primary) ; Fludarabine; Lymphokine-activated killer cells
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms T-ANK-AML
  • Most Recent Events

    • 14 Dec 2011 Favorable final results were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH-2011), according to a Coronado Biosciences media release.
    • 15 Nov 2011 Final results will be presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Coronado Biosciences media release.
    • 12 Oct 2011 United Kingdom Clinical Research Network reports accrual to date changed from 26% to 100%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top